Every 8-K that Nanovibronix Inc (NAOV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NAOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAOV filings page.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise $2,500,000 of the Additional Investment Right described in the July 18, 2025 Securities Purchase Agreement. The Certificate of Amendment was filed with the Delaware Secretary of State on January 30, 2026 and became effective upon filing, modifying the rights and preferences of the Series H preferred shares.
ENvue Medical, Inc., formerly known as NanoVibronix, Inc., has amended its certificate of incorporation to change its corporate name to ENvue Medical, Inc., effective December 12, 2025. On the same date, its common stock stopped trading on Nasdaq under the ticker symbol “NAOV” and began trading under the new symbol “FEED.”
The company states that the name change and ticker change do not affect the rights of its security holders and that its CUSIP remains the same. Under Delaware law, this amendment did not require stockholder approval. The company also issued a press release on December 12, 2025 to announce the name and symbol changes.
NanoVibronix, Inc. (NAOV) filed a current report announcing that it issued a shareholder letter on November 19, 2025. The letter was provided to investors as an exhibit to this report under a disclosure rule that covers company communications with the market, rather than as a formal financial or earnings filing. The report clarifies that this communication is being furnished, not filed, which means it is not automatically incorporated into other securities law filings or subject to certain legal liabilities.
NanoVibronix (NAOV) reported board changes under Item 5.02. On October 30, 2025, Christopher Fashek, Thomas Mika, Martin Goldstein, M.D., and Brian Murphy notified the Board that they will not stand for reelection and will retire from the Board and all committees, effective immediately prior to the 2025 Annual Meeting of Stockholders.
The filing notes their decisions were for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices. As of the notice date, Mr. Fashek served on the Audit, Nominating and Corporate Governance, and Compensation Committees; Mr. Mika served on the Audit and Compensation Committees; and Dr. Goldstein served on the Nominating and Corporate Governance Committee.
NanoVibronix, Inc. entered into a securities purchase agreement with a single institutional investor for a registered direct offering of equity. The company agreed to sell 74,114 shares of common stock and prefunded warrants to purchase up to 217,090 additional shares, all under an effective shelf registration. The offering price was $7.01 per share of common stock and $7.009 per prefunded warrant, reflecting a $0.001 exercise price per warrant share. NanoVibronix reports net proceeds of about $1.8 million after fees, which it currently plans to use mainly for general working capital, including repayment of certain debt and/or redemption of preferred stock. The prefunded warrants have a very low exercise price and may be exercised until fully used, subject to a 4.99% (or, at the holder’s election, 9.99%) beneficial ownership cap that can be adjusted with 61 days’ prior notice.
NanoVibronix, Inc. effected a 1-for-10 reverse stock split of its common stock, combining every ten issued or treasury shares into one share while leaving the par value unchanged. The company will not issue fractional shares; any fractional interests will be rounded up to whole shares.
The Reverse Stock Split reduces outstanding shares from 7,968,868 to approximately 796,887 (subject to rounding). Authorized common shares remain 40,000,000. The common stock will trade on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker NAOV, and the company provided a new CUSIP. Outstanding equity awards and plan reserves will be proportionately adjusted per the terms of the 2014 and 2024 plans. The Certificate of Amendment and a press release are filed as exhibits.